Background
Methods
Study population
Sample collection and genotyping
Statistical analysis
Results
Basic information of the study population and SNPs
Characteristics | Cases (459) | Controls (549) | P-value |
---|---|---|---|
Age (mean ± SD) | 49.09 ± 11.02 | 48.80 ± 8.28 | 0.610 |
Menopausal status
| 0.376 | ||
Premenopausal | 237 | 267 | |
Postmenopausal | 222 | 282 | |
Procreative times
| 0.657 | ||
< 2 | 242 | 298 | |
≥ 2 | 217 | 251 | |
BMI (kg/m2, mean ± SD) | 23.06 ± 2.92 | 22.45 ± 2.53 | 0.274 |
Rs number | Gene symbol | Allele | Chromosome position | MAF |
P
HWE
|
---|---|---|---|---|---|
rs2881766 |
ESR1
| G/T | Chr6:151797984 | 0.452 | 0.556 |
rs9383951 |
ESR1
| C/G | Chr6:151974478 | 0.068 | 0.662 |
rs9340799 |
ESR1
| A/G | Chr6:151842246 | 0.281 | 0.797 |
rs3020449 |
ESR2
| C/T | Chr14:64306674 | 0.484 | 0.501 |
Association between ESR1 and ESR2 SNPs with BC risk
Model | Genotype | Cases (n, %) | Control (n, %) | OR (95% CI) | P-value | AIC | BIC |
---|---|---|---|---|---|---|---|
rs2881766
| 459 | 549 | |||||
Codominant | TT | 173 (37.7%) | 178 (32.4%) | 1.00 | – | – | – |
GT | 218 (47.5%) | 260 (47.4%) | 0.87 (0.66–1.15) | – | – | – | |
GG | 68 (14.8%) | 111 (20.2%) | 0.63 (0.44–0.91) |
0.046
| 1387.9 | 1412.5 | |
Dominant | TT | 173 (37.7%) | 178 (32.4%) | 1.00 | – | – | – |
GT/GG | 286 (62.3%) | 371 (67.6%) | 0.80 (0.62–1.04) | 0.091 | 1389.2 | 1408.9 | |
Recessive | TT/GT | 391 (85.2%) | 438 (79.8%) | 1.00 | – | – | – |
GG | 68 (14.8%) | 111 (20.2%) | 0.68 (0.49–0.95) |
0.022*
| 1386.9 | 1406.5 | |
Overdominant | TT/GG | 241 (52.5%) | 289 (52.6%) | 1.00 | – | – | – |
GT | 218 (47.5%) | 260 (47.4%) | 1.02 (0.79–1.30) | 0.9 | 1392.1 | 1411.7 | |
rs9383951
| 458 | 549 | |||||
Codominant | GG | 379 (82.8%) | 442 (80.5%) | 1.00 | – | – | – |
GC | 76 (16.6%) | 102 (18.6%) | 0.89 (0.64–1.23) | – | – | – | |
CC | 3 (0.7%) | 5 (0.9%) | 0.77 (0.18–3.28) | 0.74 | 1391.7 | 1416.3 | |
Dominant | GG | 379 (82.8%) | 442 (80.5%) | 1.00 | – | – | – |
GC/CC | 79 (17.2%) | 107 (19.5%) | 0.88 (0.64–1.22) | 0.45 | 1389.8 | 1409.4 | |
Recessive | GG/GC | 455 (99.3%) | 544 (99.1%) | 1.00 | – | – | – |
CC | 3 (0.7%) | 5 (0.9%) | 0.79 (0.19–3.35) | 0.75 | 1390.3 | 1409.9 | |
Overdominant | GG/CC | 382 (83.4%) | 447 (81.4%) | 1.00 | – | – | – |
GC | 76 (16.6%) | 102 (18.6%) | 0.89 (0.64–1.24) | 0.48 | 1389.9 | 1409.5 | |
rs9340799
| 459 | 549 | |||||
Codominant | AA | 289 (63%) | 349 (63.6%) | 1.00 | – | – | – |
GA | 144 (31.4%) | 179 (32.6%) | 0.97 (0.74–1.27) | – | – | – | |
GG | 26 (5.7%) | 21 (3.8%) | 1.44 (0.79–2.62) | 0.44 | 1392.5 | 1417.0 | |
Dominant | AA | 289 (63%) | 349 (63.6%) | 1.00 | – | – | – |
GA/GG | 170 (37%) | 200 (36.4%) | 1.02 (0.79–1.32) | 0.89 | 1392.1 | 1411.7 | |
Recessive | AA/GA | 433 (94.3%) | 528 (96.2%) | 1.00 | – | – | – |
GG | 26 (5.7%) | 21 (3.8%) | 1.46 (0.81–2.63) | 0.21 | 1390.5 | 1410.2 | |
Overdominant | AA/GG | 315 (68.6%) | 370 (67.4%) | 1.00 | – | – | – |
GA | 144 (31.4%) | 179 (32.6%) | 0.94 (0.72–1.23) | 0.67 | 1391.9 | 1411.6 | |
rs3020449
| 459 | 549 | |||||
Codominant | TT | 176 (38.3%) | 267 (48.6%) | 1.00 | – | – | – |
CT | 230 (50.1%) | 224 (40.8%) | 1.58 (1.21–2.06) | – | – | – | |
CC | 53 (11.6%) | 58 (10.6%) | 1.39 (0.91–2.11) |
0.003
| 1382.5 | 1407.1 | |
Dominant | TT | 176 (38.3%) | 267 (48.6%) | 1.00 | – | – | – |
CT/CC | 283 (61.7%) | 282 (51.4%) | 1.54 (1.20–1.98) |
8e−04*
| 1380.8 | 1400.5 | |
Recessive | TT/CT | 406 (88.5%) | 491 (89.4%) | 1.00 | – | – | – |
CC | 53 (11.6%) | 58 (10.6%) | 1.10 (0.74–1.64) | 0.64 | 1391.9 | 1411.5 | |
Overdominant | TT/CC | 229 (49.9%) | 325 (59.2%) | 1.00 | – | – | – |
CT | 230 (50.1%) | 224 (40.8%) | 1.48 (1.15–1.90) |
0.002
| 1382.8 | 1402.5 |
FPRP analysis results
Model | OR (95% CI) | Prior probability | |||
---|---|---|---|---|---|
0.25 | 0.1 | 0.01 | 0.001 | ||
ESR1 rs2881766
| |||||
GG vs.TT | 0.63 (0.44–0.91) | 0.100* |
0.250*
| 0.786 | 0.974 |
GG vs.TT/GT | 0.68 (0.49–0.95) | 0.118* | 0.286 | 0.815 | 0.978 |
ESR2 rs3020449
| |||||
CT vs.TT | 1.58 (1.21–2.06) | 0.006* |
0.018*
| 0.170* | 0.674 |
CT/CC vs.TT | 1.54 (1.20–1.98) | 0.005* |
0.016*
| 0.152* | 0.644 |
CT vs.TT/CC | 1.48 (1.15–1.90) | 0.011* |
0.034*
| 0.277 | 0.795 |
Relationship of rs2881766 and rs3020449 with clinicopathological features of BC
Variables | Genotype | OR (95% CI) | |||||
---|---|---|---|---|---|---|---|
TT | GT | GG | GG vs.TT | GT vs.TT | GT/GG vs.TT | GG vs. TT/GT | |
Tumor size (cm)
| |||||||
< 2 | 55 | 72 | 25 | ||||
≥ 2 | 118 | 146 | 43 | 0.80 (0.45–1.44) | 0.95 (0.62–1.45) | 0.91 (0.61–1.36) | 0.83 (0.48–1.41) |
LN metastasis
| |||||||
No | 60 | 88 | 36 | ||||
Yes | 113 | 130 | 32 |
0.47 (0.27–0.83)
| 0.78 (0.52–1.19) | 0.69 (0.47–1.03) |
0.54 (0.32–0.91)
|
Histological grade
| |||||||
SBR 1–2 | 89 | 117 | 38 | ||||
SBR 3 | 84 | 101 | 30 | 0.84 (0.48–1.47) | 0.91 (0.61–1.36) | 0.90 (0.61–1.31) | 0.88 (0.52–1.48) |
Venous invasion
| |||||||
None–little | 106 | 140 | 46 | ||||
Moderate-severe | 67 | 78 | 22 | 0.76 (0.42–1.37) | 0.88 (0.58–1.33) | 0.85 (0.58–1.26) | 0.81 (0.47–1.40) |
ER
| |||||||
(−) | 71 | 92 | 39 | ||||
(+) | 102 | 126 | 29 |
0.52 (0.29–0.91)
| 0.95 (0.64–1.43) | 0.82 (0.56–1.21) |
0.53 (0.32–0.90)
|
PR
| |||||||
(−) | 75 | 100 | 33 | ||||
(+) | 98 | 118 | 35 | 0.81 (0.46–1.42) | 0.90 (0.60–1.35) | 0.88 (0.60–1.29) | 0.86 (0.51–1.44) |
Her-2
| |||||||
(−) | 128 | 155 | 47 | ||||
(+) | 45 | 63 | 21 | 1.27 (0.69–2.35) | 1.16 (0.74–1.81) | 1.18 (0.77–1.81) | 1.17 (0.67–2.05) |
Ki–67 (%)
| |||||||
< 14 | 109 | 140 | 45 | ||||
≥ 14 | 64 | 78 | 23 | 0.87 (0.48–1.57) | 0.95 (0.63–1.44) | 0.93 (0.63–1.38) | 0.90 (0.52–1.54) |
Variables | Genotype | OR (95% CI) | |||||
---|---|---|---|---|---|---|---|
TT | CT | CC | CC vs.TT | CT vs.TT | CT/CC vs.TT | CC vs. TT/CT | |
Tumor size (cm)
| |||||||
< 2 | 69 | 66 | 17 | ||||
≥ 2 | 107 | 164 | 36 | 1.37 (0.71–2.62) |
1.60 (1.06–2.43)
|
1.55 (1.05–2.31)
| 1.057 (0.57–1.95) |
LN metastasis
| |||||||
No | 74 | 90 | 20 | ||||
Yes | 102 | 140 | 33 | 1.20 (0.64–2.25) | 1.13 (0.76–1.68) | 1.14 (0.78–1.67) | 1.12 (0.62–2.02) |
Histological grade
| |||||||
SBR 1–2 | 101 | 121 | 22 | ||||
SBR 3 | 75 | 109 | 31 |
1.90 (1.02–3.54)
| 1.21 (0.82–1.80) | 1.32 (0.90–1.93) | 1.70 (0.95–3.04) |
Venous invasion
| |||||||
None-little | 114 | 146 | 32 | ||||
Moderate-severe | 62 | 84 | 21 | 1.21 (0.64–2.27) | 1.06 (0.70–1.59) | 1.08 (0.73–1.61) | 1.17 (0.65–2.10) |
ER
| |||||||
(−) | 85 | 101 | 16 | ||||
(+) | 91 | 129 | 37 |
2.16 (1.12–4.17)
| 1.19 (0.80–1.77) | 1.33 (0.91–1.94) |
1.96 (1.05–3.63)
|
PR
| |||||||
(−) | 83 | 102 | 23 | ||||
(+) | 93 | 128 | 30 | 1.16 (0.63–2.16) | 1.12 (0.76–1.66) | 1.13 (0.77–1.65) | 1.09 (0.61–1.94) |
Her-2
| |||||||
(−) | 120 | 175 | 35 | ||||
(+) | 56 | 55 | 18 | 1.10 (0.57–2.11) | 0.67 (0.43–1.04) | 0.74 (0.49–1.13) | 1.37 (0.74–2.51) |
Ki–67 (%)
| |||||||
< 14 | 112 | 153 | 29 | ||||
≥ 14 | 64 | 77 | 24 | 1.45 (0.78–2.70) | 0.88 (0.58–1.33) | 0.97 (0.66–1.44) | 1.56 (0.87–2.77) |